高级检索

医防融合院内丙肝消除模式对HCV抗体阳性者检测、治疗和随访效果评价

Evaluation of the effectiveness of hepatitis C elimination by medical and preventive integration in hospital for the screening, treatment, and follow-up of HCV antibody-positive cases

    摘要
  • 摘要:
    目的 评价医防融合院内丙型病毒性肝炎（丙肝）消除模式对丙肝病毒（HCV）抗体阳性者检测、治疗和随访效果，为制定简便、易行、推广性强的院内消除丙肝危害策略提供科学依据。
    方法 在云南省玉溪市人民医院采用前后对比的准实验研究，第一阶段于2023年7—9月由院内主导对院内开展HCV抗体筛查的22 538例就诊者进行调查；第二阶段于2023年10—12月由医院联合当地疾病预防控制中心、民政局等多部门对院内开展HCV抗体筛查的19 582例就诊者进行调查。本研究收集2个阶段不同性别、年龄、样本来源就诊患者HCV抗体筛查数、HCV抗体阳性者丙肝病毒核酸（HCV RNA）检测数、HCV RNA阳性数、HCV RNA阳性者治疗数、接受丙肝治疗者治疗完成数和治疗完成后12周随访数等数据对比分析2个阶段HCV抗体阳性者HCV RNA检测、治疗和随访效果。
    结果 玉溪市人民医院2023年7—12月HCV筛查就诊者的HCV抗体阳性率为0.79%（332/42 120），HCV抗体阳性者的HCV RNA检测率为61.14%（203/332），HCV RNA阳性者的治疗率为64.42%（67/104），接受治疗者总体治疗完成后12周的随访率为81.82%（54/66）；其中，第一阶段和第二阶段HCV筛查者HCV抗体阳性率、HCV抗体阳性者HCV RNA检测率、HCV RNA阳性者治疗率、接受治疗者总体治疗完成后12周随访率分别为0.82%（185/22 538）和0.75%（147/19 582）、36.76%（68/185）和91.84%（135/147）、37.14%（13/35）和78.26%（54/69）、58.33%（7/12）和87.04%（47/54）；2个阶段比较，除HCV筛查者HCV抗体阳性率2个阶段差异无统计学意义外（P>0.05），第二阶段HCV抗体阳性者HCV RNA检测率、HCV RNA阳性者治疗率和接受治疗者总体治疗完成后12周随访率均较第一阶段显著提高（均P<0.05）。
    结论 医防融合院内丙肝消除模式能显著提升HCV抗体阳性者的HCV RNA检测率、治疗率和随访率，可助力消除丙肝危害。

     

    Abstract:
    Objective To evaluate the effectiveness of hepatitis C elimination by medical and preventive integration in hospital for the screening, treatment, and follow-up of hepatitis C virus (HCV) antibody-positive cases and provide a scientific basis and reference for formulating simple, feasible, and promotable strategies for eliminating the hazard of hepatitis C in hospital.
    Methods A quasi-experimental before-after study was carried out in the People′s Hospital of Yuxi City in Yunnan province. The first phase was conducted from July to September 2023, led by the hospital to investigate 22 538 cases of HCV screening in the hospital. The second phase was conducted from October to December 2023 jointly by the hospital, center for disease control and prevention, civil affairs bureau to investigate 19 582 cases of HCV screening in the hospital. In this study, the data of HCV antibody screening, HCV RNA testing, HCV RNA positivity, HCV treatment completion for those receiving treatment, and follow-up 12 weeks post-treatment were collected regarding different genders, ages, and sample sources in the two phases. The effectiveness of HCV RNA testing, treatment, and follow-up were compared between the two phases.
    Results In the People′s Hospital of Yuxi City from July to December 2023, the HCV antibody-positive rate was 0.79% (332/42 120) in HCV screening cases. The HCV RNA testing rate of HCV antibody-positive cases was 61.14% (203/332). The treatment rate of HCV RNA-positive cases was 64.42% (67/104), and the follow-up rate of 12 weeks post-treatment was 81.82% (54/66). The HCV antibody-positivity rate, HCV RNA testing rate of HCV RNA-positive cases, treatment rate of HCV RNA-positive cases, and follow-up rate of 12 weeks post-treatment in the first and second phases were 0.82% (185/22 538) and 0.75% (147/19 582), 36.76% (68/185) and 91.84% (135/147), 37.14% (13/35) and 78.26% (54/69), and 58.33% (7/12) and 87.04% (47/54), respectively. Excepted that the HCV antibody-positive rate showed no statistically significant difference between the two phases (P > 0.05), the HCV RNA testing rate of HCV RNA-positive cases, treatment rate of HCV RNA-positive cases, and follow-up rate of 12 weeks post-treatment in the second phase were higher than those in the first phase (all P < 0.05).
    Conclusions The hepatitis C elimination by medical and preventive integration in hospital can significantly increase the HCV RNA testing rate, treatment rate, and follow-up rate of HCV RNA-positive cases, thus helping eliminate the hazards of hepatitis C in hospital.

     

    • HTML全文
    • 参考文献(21)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回